Bristol-Myers AASLD hepatitis C data focus on hard-to-treat
This article was originally published in Scrip
Executive Summary
Hepatitis C is a difficult market to enter when new drugs with high cure rates are instant blockbusters, but the strategy at Bristol-Myers Squibb is to focus on difficult populations, such as patients with genotype 3 hepatitis C virus (HCV) or genotype 1 HCV patients with cirrhosis or HIV, and potentially shorten the duration of treatment.